PDCD1 and non-small cell lung carcinoma: The second article is a review of the adverse events profile of anti-programmed cell death-1 or anti cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibodies.[56] The third high cited article believed that the treatment of low-grade or transformed non-Hodgkin lymphoma with iodine I-131 tositumomab has good responses.[57] The 4th article is Osmani, Lais et al[58] review of World Health Organization’s classification of non-small cell lung-cancer published in 2018.